GMED vs. RMD, STE, BAX, HOLX, PODD, TFX, MASI, ITGR, IART, and ATEC
Should you be buying Globus Medical stock or one of its competitors? The main competitors of Globus Medical include ResMed (RMD), STERIS (STE), Baxter International (BAX), Hologic (HOLX), Insulet (PODD), Teleflex (TFX), Masimo (MASI), Integer (ITGR), Integra LifeSciences (IART), and Alphatec (ATEC). These companies are all part of the "health care equipment" industry.
ResMed (NYSE:RMD) and Globus Medical (NYSE:GMED) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.
ResMed has higher revenue and earnings than Globus Medical. ResMed is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.
Globus Medical received 131 more outperform votes than ResMed when rated by MarketBeat users. Likewise, 67.83% of users gave Globus Medical an outperform vote while only 52.93% of users gave ResMed an outperform vote.
55.0% of ResMed shares are held by institutional investors. Comparatively, 95.2% of Globus Medical shares are held by institutional investors. 1.2% of ResMed shares are held by insiders. Comparatively, 18.5% of Globus Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
ResMed has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, Globus Medical has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500.
ResMed has a net margin of 20.91% compared to ResMed's net margin of 3.51%. Globus Medical's return on equity of 24.43% beat ResMed's return on equity.
ResMed currently has a consensus target price of $202.80, indicating a potential downside of 2.11%. Globus Medical has a consensus target price of $68.50, indicating a potential upside of 4.61%. Given ResMed's higher probable upside, analysts clearly believe Globus Medical is more favorable than ResMed.
In the previous week, ResMed and ResMed both had 5 articles in the media. ResMed's average media sentiment score of 1.23 beat Globus Medical's score of 0.88 indicating that Globus Medical is being referred to more favorably in the news media.
Summary
ResMed and Globus Medical tied by winning 8 of the 16 factors compared between the two stocks.
Get Globus Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for GMED and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GMED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Globus Medical Competitors List
Related Companies and Tools
